编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

近日，Signal Transduction and Targeted Therapy期刊上发表了同样来自复旦大学附属中山医院樊嘉院士及史颖弘、代智等研究者的研究成果：抑制SRSF1一方面能够全面提升CD8 + ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

在Nature Cancer期刊以长文的形式发表了题为“ETV7 limits the antiviral and anti-tumor efficacy of CD8+ T cells by diverting their fate towards exhaustion （ETV7通过促进CD8+ T细胞命运向耗竭的转化，限制CD8+ T细胞抗病毒和抗肿瘤的功能）的研究论文 CD8 + ...

In summary, this study revealed the role of aging in compromising the anti-tumor immune response of CD8 + T cells and the molecular mechanism involved. Further investigation of inhibitors ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." The study authored by Dr. Steven A.